2

Confidential

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation ReformAct of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historicalfact are statements that could be deemed forward-looking statements, including any statements of the plans,strategies and objectives of management for future operations; any statements regarding product development,product extensions, product integration or product marketing; any statements regarding continued compliance withgovernment regulations, changing legislation or regulatory environments; any statements of expectation or belief andany statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related tosuccessfully integrating the products and employees of the Company and Radiancy, as well as the ability to ensurecontinued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors,and the general risks associated with the businesses of the Company described in the reports and other documentsfiled with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in theforward-looking statements. The Company cautions readers not to rely on these forward-looking statements. Allforward-looking statements are based on information currently available to the Company and are qualified in theirentirety by this cautionary statement. The Company anticipates that subsequent events and developments will causeits views to change. The information contained in this presentation speaks as of the date hereof and the Companyhas or undertakes no obligation to update or revise these forward-looking statements, whether as a result of newinformation, future events or otherwise.

Safe Harbor Statement

Confidential

Company Overview

4

Confidential

Key Investment Highlights§ End-to-end Product Solutions Serving the Consumer, Physician and Professional Aesthetics Markets

§ Strong Brand Recognition and Award Winning Products

§ Cross-Selling and Development Opportunities to Drive Future Growth

― Leveraging our highly successful Consumer sales engine and creative marketing programs to:

• Bring select PhotoMedex products (including the Neova brand) into the Consumer channel

• Increase the brand awareness and adoption of PhotoMedex’s current Physician Recurring Aesthetics products

― Leveraging direct sales force to drive Radiancy’s Professional Aesthetics products

§ Financial Profile

― FYE 2011 Pro Forma revenue of $162 million and adjusted income of $35 million - $1.87 per share

― 1Q12 Revenue $50.3 million and adjusted income of $10.7 million - $0.564 per share

§ Strong IP Position - 257 patents (filed and pending), 91 FDA 510(k)’s

§ Experienced Leadership with Expertise in Consumer, Physician and Professional Product Development and Sales

5

Confidential

Overview§ PhotoMedex/Radiancy Merger

― Announced: July 2011

― Closed: Dec 2011

§ NASDAQ:PHMD

§ Market Cap of $392 million

― Price (05/11/12): $17.93/shr

― Basic Shares1 O/S:21.9 million

― $20 Warrants: 1.1 million

― Options: 0.9 million

§ Pro Forma Financials

FYE 2011 1Q12

― Revenue: $162 million $50.3 million

― Adj. income: $35 million $10.7 million

1 April 27, 2012 - $40 million registered share offering completed, net proceeds approximately $38 million

6

Confidential

End-to-End Solutions§ Continued innovation in the Physician and Professional channels is complementary to our

demonstrated expertise in the Consumer channel

― Development of an idea, regulatory clearance, adoption, acceptance and validation in the Physician and Professional communities, miniaturization and delivery directly to the Consumer

7

Confidential

… Award winning products

What Other People Say About Us…

Confidential

Consumer Momentum

9

Confidential

§ Direct sales channels covering U.S., Canada, the U.K., Argentina, Uruguay, Spain, Portugal, & Israel

§ Distribution relationships in Japan, Australia, New Zealand, Singapore, Thailand, Russia, South Africa, various South American countries and the Middle East

Global Reach§ Consumer products are sold globally

― High-end retailers: ~5,000 retail outlets in 55 countries

― Company stores/kiosks

― Home shopping channels: including HSN and QVC

― Online: including Amazon.com, Dermadoctor.com, and Drugstore.com

― Direct-to-consumers: through infomercials, commercials, catalogs and internet-based marketing initiatives

10

Confidential

Select RetailersUnited States/Canada United Kingdom Australia & New Zealand

South America Japan

11

Confidential

Solta, 0.2%Syneron,

1.0%

Tria, 12.5%

Ultragen, 2.3%

Zeno, 3.5%

Others, 13.4%

Dezac, 1.1%

Home Skinovations, 5.3%

Labowell, 1.7%

Lexington, 7.1%

Pacific BioScience (1), 23.4%

Philips, 1.7%

Significant Market Share

Market Share of Top Home-Use Aesthetics Companies (by Retail Sales – Dec 2010)

§ As of the most recent data published in August 2011 for 2010 Retail Sales, the no!no! brand commanded a higher market share of global home-use retail sales than any other brand in the market

Source: “Mini Report – Home-Use Devices: Rapidly Moving Into the Mainstream.” Medical Insight, Inc. August 2011.

26.8%

(1) Pacific BioScience sells a scrubbing brush and recently sold company to Loreal

12

Confidential

§ Proprietary marketing engine allows fluid deployment of resources to lever Global Home Use trends leading to significant growth during a sustained period of staggering economy

§ Multiple Consumer Channel initiatives (Infomercial, Traditional retail stores, Online, TV retail, Kiosks) have built rapid Brand Awareness across multiple geographies

§ More than 50 Direct Response Performance Metrics tracked and monitored weekly allowing management to quickly direct resource allocation to better performing Media Agencies, Call Centers, Fulfillment houses, and Manufacturers

― Metrics by market, by type, by facility include Media ROI, Conversion Rates, Up-sell, Customer Service Scorecard, CPO, AOV etc.

Consumer Sales by Geography(FYE 2011)

Consumer Sales by Channel (FYE 2011)

Consumer Marketing Engine

* Includes U.S. and Canada.

61%23%

16%

Direct-to-Consumer

Distributors

Retailers & HSN 71%29%

North America*

International

Confidential

Technology Platforms

14

Confidential

15

Confidential

16

Confidential

Radiancy Professional LHE™ Products

Mistral Duet & Duet Pro Kona SpaTouch Elite FTD

Launched 2009 2008/2009 2008 2010 2005

Skin Rejuvenation P P P P

Hair Removal P P P P

Acne Clearance P P

Skin Tightening P

Psoriasis Care P

Physician Aesthetician

For Physician Offices, Medical Spas & Salons

17

Confidential

Reimbursed treatment of Vitiligo and Mild-to-Severe PsoriasisXTRAC™

§ The only technology available with minimal side effects

§ 89% efficacy

§ 8-12 treatments to remission vs. 30-40 treatments for the next option

§ Close to full reimbursement for psoriasis; growing reimbursement for vitiligo

§ US Market Size

― 7.5 million Psoriasis patients

― 2.5 million Vitiligo patients

― Typical reimbursement of $175 per treatment

Before After 13 treatments

After 6 months of treatment

PhotoMedexPhotoMedex6

18

Confidential

NEOVA™ – DNA + Copper Combination Therapy

§ Neova DNA + Copper Combination Therapy products offer powerful therapeutic intervention for UV-induced DNA damage and advanced delivery systems

DNA Repair Enzymes Copper Peptide Complex§ Continuously repair, enhances skin’s natural processes

§ Protect from UV immunosuppression

§ Restore barrier function

§ Promote collagen and elastin regeneration

§ Assist in correcting and improving cell metabolism

§ Promotes new blood vessel growth

§ Enhances the expression of growth factors

§ Stimulates the formation of new collagen, elastin, and tissue components to accelerate the repair process.

§ Promotes powerful antioxidant defense against free radicals

Real Science. Proven Results.

45% DecreaseUV Damage

97% DecreaseWrinkleScoresSize, area

19

Confidential

§ Omnilux™ is a three-head LED device that treats all skin types by employing the principle of photo bio-modulation

§ The system is FDA cleared for treatment of

― Periorbital wrinkles

― Acne vulgaris

― Minor muscle and joint pain

― Superficial, benign and pigmented lesions

Physicians

Spa’s & Salons

§ Non-medical application of the Omnilux technology; same patent protection

§ Combines Light Therapy with proprietary (DNA repair and Copper Peptide) topical skincare products to:

― Create even skin tone and texture

― Lighten age spots, sun spots and dark circles

― Clear and soothe problematic skin

Confidential

Growth Drivers

21

Confidential

22

Confidential

The Consumer Opportunity

Acne P P

Consumer Topicals P

Hair Removal P

Periorbital Wrinkles P

Facial Tightening P

§ Radiancy has been successful in bringing Professional technologies into the home-use market

― Over 2.5 million units sold worldwide

― Highly successful direct-to-consumer sales engine

― Creative marketing programs to drive brand awareness

§ Ability to bring Neova and other select PhotoMedex technologies into the Consumer channel

§ Strong technology platforms in the Physician and Professional markets will drive new products for the Consumer channel

Professional Technology Made for Consumers

23

Confidential

The Physician Recurring Opportunity§ Radiancy brings critical expertise in direct-to-consumer advertising and innovative

marketing programs

§ Opportunity to leverage the expanded marketing platform to drive brand awareness and adoption for XTRAC and Neova products

§ Both XTRAC and Neova represent recurring revenue streams with significant market opportunities

• Over 7.5 million Psoriasis patients and over 2.5 million Vitiligo patients in the U.S.

• Close to full reimbursement for psoriasis; growing reimbursement for vitiligo

• Comprehensive approach to medically direct skincare

• Over $30 billion in estimated global sales from anti-aging skincare products

24

Confidential

The Professional Opportunity

Acne P P

Atopic Dermatitis P

Hair Removal P

Joint Pain P

Leukoderma P

Periorbital Wrinkles P P

Physician Topicals P

Psoriasis P P

Skin Rejuvenation P P

Skin Tightening P

Vascular & Pigment Lesions P P

Vitiligo P

§ Greatly expanded product offering

§ Will leverage our 48 person domestic sales force selling into 3,000 physician dispense locations

― Radiancy Professional products generated revenue of $5.6 million for 2011 with a limited direct sales force

― Radiancy’s Professional products are based on LHE technology

§ Combined portfolio of proprietary technologies will drive product innovation in the channel

25

Confidential

Efficacy:It has to work objectively

IP Protection:Brand equity protection

Cost of Goods:Low enough to create “right” price point and good company margin

Market:Well defined, big enough and wide enough for the

product/service

Critical Success Factors

Consumer

§ Continued geographic expansion

§ Several no!no! brand extensions

§ Neova and other products into the Consumer channel

§ Technology development in Physician and Professional channels drives new products for Consumer channel

Professional§ Radiancy Professional

products in the hands of 48 person direct U.S. sales force

Physician Recurring

§ Direct-to-consumer expertise to drive XTRAC and Neova brand awareness and utilization

§ Increasing insurance reimbursement for Vitiligo

§ Clinical trial for drug / device combination - $10B market

Growth Drivers & Product Development

Confidential

Financial Overview

27

Confidential

Reported Financial Results2011 Revenues Increase 89%; Gross Profit increases 97%;

Non-GAAP Adjusted Income increases 95%

1Q12 Revenues exceed $50 million

$70.1

$132.1

$53.6

$105.8

$19.0

$37.0

$0.0

$20.0

$40.0

$60.0

$80.0

$100.0

$120.0

$140.0

2009 2010 2011

Revenue Gross Profit Normalized Earnings

(in millions, except per share data)FYE/2009 FYE/2010 FYE/2011 1Q12

Revenue $16.0 $70.1 $132.1 $50.3

Gross Profit $9.9 $53.6 $105.8 $39.0Gross Margin 61.5% 76.5% 80.1% 77.7%

Net Income $5.4 $11.6 ($0.7) $4.9Adjustments to Net Income:

D&A $0.5 $0.4 $0.6 $1.3Stock Based Comp $1.0 $0.4 $34.0 $1.8Interest - - $0.0 $0.2Major Litigation Expense - $0.3 $3.0 $1.8Merger Related Expenses/other - - $2.1 $0.5Taxes ($3.6) $6.3 ($2.0) $0.2

$3.3 $19.0 $37.0 $10.7

Non-GAAP adj. Margin 20.4% 27.1% 28.0% 21.2%

Pro Forma Basic Shares Outstanding 18,822 18,822 18,822 18,340

Adj. Non-GAAP Income Per Share 0.17$ 1.01$ 1.97$ 0.58$

Non-GAAP adj. Income

1 April 27, 2012 - $40 million registered share offering completed, net proceeds approximately $38 million

Balance Sheet as of March 31, 2012

Cash & Short-term Investments $23.5 1 Total Debt $1.6

Total Assets 157.6 Total Liabilities 38.9

Working Capital 40.0 1

Confidential

People, Intellectual Property, Facilities

29

Confidential

510(k) Patents

Originated In U.S. Row Pending Total

Israel 13 10 31 57 98

PA 72 33 59 39 131

CA 6 5 8 15 28

Total 91 48 98 111 257

OverviewPeople Patents

Location ISO Certification

Israel ISO:13485:2003

PA ISO:13485:2003

CA ISO:13485:2003

§ 600 FTE Outsourced

§ 8 Call Centers

§ 4 Fulfillment Centers

§ 10 Contract Manufacturers

FacilitiesFlexible Business Model

PA, 64

Israel, 40CA, 27

NY, 10

Remote, 50

30

Confidential

Board of DirectorsBoard Member Background

Lewis Pell

Chairman

§ 30+ years of industry experience

§ Prior: Founded Pentax Precision Instruments, American Endoscopy Inc. Versaflex Inc. Heart Technology Corp. InStent Inc., Influence Inc., Biosense Inc., Vision-Sciences, Inc.

Dr. Dolev Rafaeli

Chief Executive Officer

§ 20+ years experience managing international operations

§ Prior: USR Group, Orbotech, Motorola-Land Mobile Product Solutions division

Dennis M. McGrath

President & Chief Financial Officer

§ Prior: President and CEO of PhotoMedex, AnswerThink Consulting Group, Inc.

Dr. Yoav Ben-Dror

Vice-Chairman

§ 30+ years of experience in technology, medical devices and financial innovations

§ Prior: Cellcom, Dagon Batey-Mamguroth Le-Israel Ltd, Final Inc. InStent, Disc-O-Tech

Stephen P. Connelly

Member

§ 25+ years of industry experience in planning, development and management

§ President and Chief Operating Officer of Viasys Healthcare, Inc., Prior: Rhone Poulenc Rorer

Nahum Melumad

Member

§ Professor of Accounting and Business Law at the Columbia Business School since 1993

§ Served as a consultant and advisor to many organizations, including Bristol-Myers Squibb, General Electric, the New York Stock Exchange, and Morgan Stanley

Katsumi Oneda

Member

§ Prior: Co-founder, President, CEO of Vision-Sciences Inc.

James W. Sight

Member

§ 20+ years experience in corporate restructurings and financings

§ Prior: Feldman Mall Properties, Inc., LSB Industries, Westmoreland Coal

31

Confidential

Board Member BackgroundR. Rox Anderson, M.D.

Chairman

§ Director of the Wellman Center for Photomedicine at Massachusetts General Hospital, Harvard Medical School

John Y.M. Koo, M.D.

Member

§ Vice chairman and associate clinical professor in the Department of Dermatology at the University of California San Francisco Medical Center

Daniel Siegel, M.D.,M.S.

Member

§ Professor of Clinical Dermatology at the State University of New York at Downstate

Emil A. Tanghetti, M.D.

Member

§ Board certified dermatologist at the Center for Dermatology & Laser Surgery

James Spencer, M.D.

Member

§ Clinical Professor in the Department of Dermatology at Mount Sinai

David J. Friedman, M.D.

Member

§ Director of LaseOhr, and a board certified dermatologist and a laser surgeon

Scott Guenthner, M.D.

Member

§ Founded Dermatology Center of Indiana

Elma Baron, M.D.

Member

§ Associate professor in dermatology at University Hospitals and Case Western Reserve University

Klaus Fritz, M.D.

Member

§ Vice President and board member of the ESLD (European society of laser dermatology)

Richard Fitzpatrick, M.D.

Member

§ Laser surgery specialist. Studied Internal Medicine at USC; Dermatology at UCLA

Scientific Advisory Board

32

Confidential

Key Investment Highlights§ End-to-end Product Solutions Serving the Consumer, Physician and Professional Aesthetics Markets

§ Strong Brand Recognition and Award Winning Products

§ Cross-Selling and Development Opportunities to Drive Future Growth

― Leveraging our highly successful Consumer sales engine and creative marketing programs to:

• Bring select PhotoMedex products (including the Neova brand) into the Consumer channel

• Increase the brand awareness and adoption of PhotoMedex’s current Physician Recurring Aesthetics products

― Leveraging direct sales force to drive Radiancy’s Professional Aesthetics products

§ Financial Profile

― FYE 2011 Pro Forma revenue of $162 million and adjusted income of $35 million - $1.87 per share

― 1Q12 Revenue $50.3 million and adjusted income of $10.7 million - $0.564 per share

§ Strong IP Position - 257 patents (filed and pending), 91 FDA 510(k)’s

§ Experienced Leadership with Expertise in Consumer, Physician and Professional Product Development and Sales